Program Schedule

150
Viral Infections: Clinical Trials and Pathogenesis

Friday, October 10, 2014: 2:00 PM-3:30 PM
Room: The Pennsylvania Convention Center: 105-AB

Target Audience: Academicians, Clinicians, Fellows, Infectious diseases pediatricians, Investigators, Medical students and residents, Members-in-training, Microbiologists, Researchers, Scientists

Tracks: Adult ID, Investigative ID, Pediatric ID

Moderators:  Mark Sulkowski, MD, Johns Hopkins University School of Medicine and Ajit Limaye, MD, FIDSA, University of Washington

Presentations:
2:00 PM
ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies
Jordan J. Feld, MD, MPH ; Ola Weiland, MD ; Rui Tato Marinho, MD, PhD ; Heiner Wedemeyer, MD ; Ira M. Jacobson, MD ; Donald M. Jensen, MD ; Tarek Hassanein, MD ; Victor De Ledinghen, MD ; Moisés Diago, MD ; Lorenzo Magenta, MD ; Robert J. De Knegt, MD ; Junyuan J. Xiong, MS ; Eoin Coakley, MD ; Tolga Baykal, MD ; Fernando Tatsch, MD ; Graham R. Foster, FCRP
2:15 PM
Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis
Mark Sulkowski, MD ; Kris Kowdley, MD ; Peter Ruane, MD ; Trevor Hawkins, MD ; Richard Elion, MD ; Kimberly Workowski, MD ; Anthony Mills, MD ; Mani Subramanian, MD, PhD ; Xiao Ding, PhD ; Star Seyedkazemi, PharmD ; Robert H. Hyland, D.Phil ; Jenny C. Yang, PharmD ; Phillip S. Pang, MD, PhD ; John G. Mchutchison, MD ; Nezam Afdhal, MD ; David Wyles, MD
2:30 PM
Defining herpes simplex virus type 2 sequence heterogeneity using next generation sequencing
Christine Johnston, MD, MPH ; Amalia Magaret, PhD ; Kurt Diem ; Matthew Fitzgibbon ; Meei-Li Huang, PhD ; Stacy Selke, MS ; Anna Rashevsky ; Jairam Lingappa, MD, PhD ; Connie Celum, MD, MPH ; David M. Koelle, MD ; Anna Wald, MD, MPH, FIDSA
2:45 PM
Co-Reactivation of Human Herpesvirus 6 (HHV-6) and Cytomegalovirus (CMV) is Associated with Worse Clinical Outcome in Critically Ill Immunocompetent Adults
Joshua Hill, MD ; Paula Roa, PharmD ; Katharine Kirby, MSc ; Meei-Li Huang, PhD ; Tracy Santo, BSc ; Keith Jerome, MD, PhD ; Michael Boeckh, MD ; Ajit Limaye, MD, FIDSA
3:15 PM
Familiality of fatal measles infections in Iceland, 1882. Analysis of a reconstructed patient cohort from a major epidemic
Magnus Gottfredsson, MD, PhD ; Sandra Gunnarsdottir, BS ; Haraldur Briem, MD, PhD ; Ingileif Jonsdottir, PhD ; Kari Stefansson, MD, PhD

CME Credits:

ACPE Credits:

ACPE Number:

Disclosures:

M. Sulkowski, AbbVie: Investigator and Scientific Advisor, Consulting fee and Research grant
BMS: Investigator and Scientific Advisor, Consulting fee and Research support
Gilead: Investigator and Scientific Advisor, Consulting fee and Research support
Janssen: Investigator and Scientific Advisor, Consulting fee and Research support
Merck: Investigator and Scientific Advisor, Consulting fee and Research support

A. Limaye, Genentech: Consultant and Grant Investigator, Consulting fee
Merck: Grant Investigator, Consulting fee
Viropharma: Grant Investigator, Contracted research
Astellas: Grant Investigator, Contracted research
BioRad: Consultant, Consulting fee

See more of: Oral Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek